Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: An open-label study in 10 children with equinus gait pattern

European Journal of Neurology

Volumn 6, Issue SUPPL. 4, 1999, Pages s63-s67

  Wissel, Jörg ^a   Müller, Jörg ^a   Baldauf, Angelika ^a   Ung, Sok C ^a   Ndayisaba, Jean Pierre ^a   Stöckl, Bernd ^a   Frischhut, Bernhard ^a   Haberfellner, Hubert ^a   Poewe, Werner ^a  

^a Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

Author keywords

Botulinum toxin A; Cerebral palsy; Electromyography; Gait analysis; Spasticity

Indexed keywords

BOTULINUM TOXIN A;

ANKLE; CEREBRAL PALSY; CHILD; CINERADIOGRAPHY; CLINICAL ARTICLE; CONFERENCE PAPER; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; GAIT; GASTROCNEMIUS MUSCLE; GONIOMETRY; HUMAN; JOINT MOBILITY; KNEE; MALE; MOBILIZATION; MUSCLE TONE; PES EQUINUS; PRIORITY JOURNAL; TIBIALIS ANTERIOR MUSCLE;

EID: 0343484311     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1999.tb00037.x     Document Type: Conference Paper

References (13)

1. Aoki KR, Ismail M, Tang-Liu D, Brar B, Wheeler LA (1997). Botulinum toxin type A: from toxin to therapeutic agent. Eur J Neurol 4 (suppl 2):S1-S3.
2. Berger W, Quintern J, Dietz V (1982). Pathophysiology of gait in children with cerebral palsy. Electroencephalogr Clin Neurophysiol 53:538-548.
3. Bessou P, Dupui Ph, Montoya R, Pages B (1989). Simultaneous recording of longitudinal displacements of both feet during human walking. J Physiol (Paris) 83:102-110.
4. Boyd R, Graham HK (1997). Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 4 (suppl 2):S15-S22.
5. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E (1993). Botulinum-A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400-404.
6. Hallett M (1995). Is dystonia a sensory disorder? Ann Neurol 38:139-140.
7. Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, Schenkel A, et al. (1997). Interventional Neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28:307-313.
8. Kaji R, Rothwell JC, Katayama M, Ikeda T, Kubori T, Kohara N, et al. (1995). Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neurol 38:155-162.
9. Rosales RL, Arimura K, Takenaga S, Osame M (1996). Extrafusal and intrafusal effects in experimental botulinum toxin-A injection. Muscle Nerve 19:488-496.
10. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. (1996). Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46:1306-1310.
11. Sutherland DH, Olshen RA, Biden EN, Wyatt MP (1988). The Development of Mature Walking. Oxford: Mac Keith Press.
12. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG (1996). Injection of botulinum A toxin into gastrocnemius muscle of patients with cerebral palsy: a 3-dimensional motion analysis study. Gait Posture 4:269-279.
13. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Muller J, Poewe W (1999). Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 30:120-124.